Vivesto AB
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OASMY research report →
About the company
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers.
- CEO
- Erik Kinnman
- IPO
- 2015
- Employees
- 4
- HQ
- Solna, MD, SE
Price Chart
- Market Cap
- $20.61K
- P/E
- -159.78
- P/S
- 0.00
- P/B
- 42.77
- EV/EBITDA
- -1.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -23.13%
- ROIC
- -19.56%
- Revenue
- $0 · 0.00%
- Net Income
- $-32,036,734 · 19.41%
- EPS
- $-0.48 · 0.00%
- Op Income
- $-34,377,000
- FCF YoY
- 7.27%
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 1.75
- Avg Volume
- 17
Get TickerSpark's AI analysis on OASMY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our OASMY coverage
Recent articles, reports, and earnings notes.
No research on OASMY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OASMY report →Similar companies
Peers in the same neighborhood.